VADS SANTAL ( GORTEC 2016-02) A Phase III Randomized Study of Chemo-radiotherapy Versus Radiotherapy Alone in the Adjuvant Treatment of Salivary Glands and Nasal Tumors Paris VALENTIN CALUGARU
Recherches "plusieurs pathologies" STARTRK-2 - GO40782 A Phase 2, Multicenter, Open-Label Study of Entrectinib for the Treatment of Locally Advanced or Metastatic NSCLC in Adult Patients with Tumors That Harbor NTRK1, NTRK2, NTRK3 or ROS1 Molecular Alterations Paris CHRISTOPHE LE TOURNEAU
VADS U31287-A-U203 / Patritumab RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 2 STUDY OF PATRITUMAB (U3-1287) IN COMBINATION WITH CETUXIMAB PLUS PLATINUM-BASED THERAPY IN FIRST LINE SETTING IN SUBJECTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK. Paris CHRISTOPHE LE TOURNEAU
Recherches "plusieurs pathologies" CUPISCO (MX39795) A PHASE II, RANDOMIZED, ACTIVE-CONTROLLED, MULTI-CENTER STUDY COMPARING THE EFFICACY AND SAFETY OF TARGETED THERAPY OR CANCER IMMUNOTHERAPY GUIDED BY GENOMIC PROFILING VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH CANCER OF UNKNOWN PRIMARY SITE WHO HAVE RECEIVED THREE CYCLES OF PLATINUM DOUBLET CHEMOTHERAPY. Paris CHRISTOPHE LE TOURNEAU
Appareil pulmonaire AMG20200491 - DeLLPhi-301 A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment. Paris PAULINE DU RUSQUEC
Appareil pulmonaire MARIPOSA-2 (61186372NSC3002) A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure Paris NICOLAS GIRARD
Appareil pulmonaire PECATI (MedOPP341) A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic Carcinoma PaTIents. PECATI. Paris NICOLAS GIRARD
Appareil pulmonaire CheckMate 384 (CA209-384) A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks Paris CATHERINE DANIEL
Appareil pulmonaire FRACTION-LUNG (CA018-001) A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung) Paris EMANUELA ROMANO
VADS Javelin HN100 (B9991016) A Randomized Double-blind Phase 3 Study Of Avelumab In Combination With Standard Of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) Versus Standard Of Care Chemoradiotherapy In The Front-line Treatment Of Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck. Paris CHRISTOPHE LE TOURNEAU